ERECTILE DYSFUNCTION MARKET SIZE IS EXPECTED TO REACH REVENUES OF OVER USD 4.25 BILLION BY 2023

Erectile Dysfunction Market Size, Share, Trends, Analysis Report by Therapy Type (Drug Therapies (Oral Therapies, Topical Therapies, and Intrauretheral Suppositories & Penile Injection Therapies) and Devices Therapies (Vacuum Erection Devices, Penile Implants, and Others)) and Geography (North America, APAC, Europe, Latin America, and Middle East & Africa) Industry Analysis Report, Regional Outlook, Growth Trends, Competitive Landscape, Share & Forecast, 2018–2023

GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Customize this Report

Most Exhaustive Report

182 Pages

27 Tables

90 Charts

5 Regions

13 Countries

17 Companies

3 Market Segment

Erectile Dysfunction Market REPORT SCOPE

Report Attribute Details
MARKET SIZE (REVENUE) USD 4.25 Billion (2023)
BASE YEAR 2017
Forecast YEAR 2018-2023
Market Segments Therapy Type (Drug Therapies (Oral Therapies, Topical Therapies, and Intrauretheral Suppositories & Penile Injection Therapies) and Devices Therapies (Vacuum Erection Devices, Penile Implants, and Others))
Geographic Analysis North America, APAC, Europe, Latin America, and Middle East & Africa
Countries Covered US, Canada, Germany, UK, France, Italy, Spain, Japan, India, China, Australia, Brazil, and Mexico

INDSUTRY INSIGHTS

Increasing disease awareness, growing patient willingness to seek medical assistance for disease management, and the increasing presence of favorable guidelines are driving the growth of the erectile dysfunction market. The three most popular erectile dysfunction drugs that are available are ED oral drugs, Viagra, Cialis, and Levitra. The global market is also witnessing a rising demand for low-cost generic drugs, especially in the APAC countries such as Indian and China. The US and Europe are the main revenue contributors during the forecast period. The growing number of chronic medical conditions such as diabetes, hypertension, dyslipidemia, and coronary heart disease across the globe is also increasing the number of erectile dysfunction patients and boosting the demand for therapeutics segment. The increasing investments in R&D for the development of new drugs and clinical trials will augment the growth.

The growing awareness of male sexual health conditions and the increasing healthcare spending for sexual wellness, especially in the APAC region will propel the development of the market. The introduction of innovative drug therapy will have a positive impact on the growth. The introduction of innovative drug therapy will have a positive impact on the growth of the erectile dysfunction market.

Key highlights

  • A high prevalence rate of conditions like benign prostate hyperplasia, diabetes, high blood pressure, and high cholesterol can lead to increase in the number of the erectile dysfunction population.
  • Another major market enabler is the significant increase in disease awareness among the people worldwide. This has propelled the volume of treatment-seeking population.
  • The medical devices industry has witnessed significant advances in device technology such as device manufacturing, the inclusion of precise and customizable product features, and other technological advances.
  • The emergence of advanced drug formulations such as oral drug therapies, and topical therapies has dominated the global market.
  • Mergers and acquisitions will allow players to gain competitive advantage with a wide product portfolio, vast geographical reach, and increased growth and profitability.

Market Dynamics

Increase in strategic agreements and consolidations among the leading vendors to expand their services or product portfolios is likely to contribute to the growth of the global market. Mergers and acquisitions will allow players to gain competitive advantage with a wide product portfolio and vast geographical reach, thereby driving the growth and profitability of vendors. These strategic consolidations and mergers will help prominent companies to expand their businesses in emerging regions and widen their distribution networks to attract a large consumer base. For instance, a licensing agreement between A. Menarini Asia-Pacific and Mitsubishi Tanabe Pharma was signed to commercialize and promote avanafil in China, Hong Kong, Taiwan, Macao, the Philippines, Singapore, Indonesia, Malaysia, Thailand, and Vietnam.

Erectile Dysfunction Market Segmentation

This research report includes a detailed segmentation by

  1. Therapy
  2. Geography

Insights by Therapy Type

Drugs therapy type to dominate the erectile dysfunction market shares during the forecast period

The therapy type segment is classified into drugs and devices. The erectile dysfunction drug market dominated; accounting for close to 89% of the total share in 2017 and is expected to generate revenue of about $3,487.41 million during the forecast period. Preferability for needle-free penile injection kits and increase in disease awareness will fuel the growth of this drug segment. The market for other drug therapy types, topical agents, intraurethral suppositories, and intracavernosal injections is expected to grow at a moderate pace over the next few years. The segment will also observe a negative growth due to the patent expiration of generic versions of key oral drugs Viagra, Cialis, and Levitra during the forecast period.

Insights by Geography

North America to occupy the largest erectile dysfunction market share during the forecast period

The geographical segment is divided into APAC, Europe, Latin America, MEA, and North America. North America dominated occupying more than 43% of the total the global erectile dysfunction market share in 2017 and is expected to generate the revenue of $1,832.82 million by 2023. Factors such as better access to ED treatments and reimbursement coverage for high post penile implant surgeries is fueling the growth in North America region. The erectile dysfunction U.S. market size accounts for more than 90% of the total share in the North America. The high uptake and access to both prescription and OTC devices in North America is attributing the highest revenue in this region. Moreover, increasing penile implantation surgical procedures, growing e-commerce sales of penile erection devices, and rising preference for advanced non-invasive devices will have a positive impact on the growth in North America.

Key Vendor Analysis

The erectile dysfunction market is oligopolistic, as a limited number of major players occupies the predominant shares. A minority of the shares has occupied by a surfeit of specialty and generic drug companies. The strategic initiatives adopted by the leading and other prominent companies will intensify the competition during the forecast period. The leading companies are focusing on leveraging their strengths to diversify their product portfolios and increase their global presence. The entry of new players and the introduction of innovative therapeutics will increase the level of competition during the forecast period.

Major Vendors

  • Bayer AG
  • Eli Lilly and Company
  • VIVUS Inc.
  • Pfizer
  • Boston Scientific Corp.
  • Coloplast A/S

The erectile dysfunction market analysis report includes in-depth coverage of the industry analysis with revenue and forecast insights for the following segments:

By Therapy Type

  • ED Drugs
    • Oral Therapies
    • Topical Therapies
    • Intrauretheral suppositories & Penile injection therapies
  • ED Devices
    • Vacuum erection devices
    • Penile Implants
    • Others

By Geography

  • North America
    • US
    • Canada
  •  Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
  • APAC
    • Japan
    • India
    • China
    • Australia
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa

Frequently Asked Questions

Erectile dysfunction market size is expected to reach revenues of over USD 4.25 billion by 2023
The erectile dysfunction drug market dominated; accounting for close to 89% of the total share in 2017 and is expected to generate revenue of about $3 billion during the forecast period.
North America dominated occupying more than 43% of the total the global erectile dysfunction market share in 2017
Bayer AG, Eli Lilly and Company, VIVUS Inc., Pfizer, Boston Scientific Corp., and Coloplast A/S are the major vendors in the market.
Read More

Select a license type that suits your business needs

Single User Licence
$4000.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5 User Licence
$4500.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
$5000.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
$2000.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Select a license type that suits your business needs

Best Value Tag
Coming Soon
  • Stay tuned with us.

YOU CAN GET A FREE SAMPLE OF THIS REPORT!

Fill out your details & get your free sample

Our Clients

Licence Types What are these?

Our Clients Speak

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date